Avadel Pharmaceuticals plc settled litigation with Jazz Pharmaceuticals Inc., granting Avadel a license to Jazz patents and $90 million payment. Jazz will waive royalties on past sales of LUMRYZ and not challenge future FDA approvals. Avadel will pay royalties to Jazz on net sales of LUMRYZ through 2036. LUMRYZ is FDA-approved for narcolepsy and idiopathic hypersomnia. Important safety information includes warnings of CNS depressants and sodium oxybate misuse. LUMRYZ can cause side effects like breathing problems and mental health issues. Avadel focuses on transforming medicines, like LUMRYZ, to improve patient care.

Read more at GlobeNewswire: Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach